These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 1794262)

  • 1. The mode of action and clinical pharmacology of gliclazide: a review.
    Campbell DB; Lavielle R; Nathan C
    Diabetes Res Clin Pract; 1991; 14 Suppl 2():S21-36. PubMed ID: 1794262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemobiological activity of gliclazide in diabetes mellitus.
    Ziegler O; Drouin P
    Diabetes Res Clin Pract; 1991; 14 Suppl 2():S83-9. PubMed ID: 1794271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus.
    Holmes B; Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1984 Apr; 27(4):301-27. PubMed ID: 6373223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The physiological action of gliclazide: beta-cell function and insulin resistance.
    Matthews DR; Hosker JP; Stratton I
    Diabetes Res Clin Pract; 1991; 14 Suppl 2():S53-9. PubMed ID: 1794266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus.
    Palmer KJ; Brogden RN
    Drugs; 1993 Jul; 46(1):92-125. PubMed ID: 7691511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of gliclazide on plasma insulin, intact and 32/33 split proinsulin in South Asian subjects with Type 2 diabetes mellitus.
    Ammari F; Davies MJ; Koppiker N; Gregory R; Burden AC
    Diabet Med; 1999 Feb; 16(2):142-6. PubMed ID: 10229308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of cellular actions between gliclazide and a hypoglycaemic peptide fragment of human growth hormone (hGH 6-13).
    Ng FM
    Diabetes Res Clin Pract; 1988 May; 5(1):17-24. PubMed ID: 3042343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: a two-year controlled study.
    Larkins RG; Jerums G; Taft JL; Godfrey H; Smith IL; Martin TJ
    Diabetes Res Clin Pract; 1988 Jan; 4(2):81-7. PubMed ID: 3125029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gliclazide: review of metabolic and vascular action].
    Alberti KG
    Diabete Metab; 1994 Nov; 20(3 Pt 2):341-8. PubMed ID: 7828778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gliclazide and insulin action in human muscle.
    Bak JF; Pedersen O
    Diabetes Res Clin Pract; 1991; 14 Suppl 2():S61-4. PubMed ID: 1794267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unchanged gene expression of glycogen synthase in muscle from patients with NIDDM following sulphonylurea-induced improvement of glycaemic control.
    Vestergaard H; Lund S; Bjørbaek C; Pedersen O
    Diabetologia; 1995 Oct; 38(10):1230-8. PubMed ID: 8690177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic cause of hyperglycaemia and response to treatment in diabetes.
    Pearson ER; Starkey BJ; Powell RJ; Gribble FM; Clark PM; Hattersley AT
    Lancet; 2003 Oct; 362(9392):1275-81. PubMed ID: 14575972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes.
    Baba S; Nakagawa S; Takebe K; Goto Y; Maezawa H; Takeda R; Sakamoto N; Fukui I
    Tohoku J Exp Med; 1983 Dec; 141 Suppl():693-706. PubMed ID: 6440313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of beta-cell function after long-term treatment with either insulin, insulin plus gliclazide or gliclazide in neonatal streptozotocin-induced non-insulin-dependent diabetic rats.
    Kawai K; Suzuki S; Murayama Y; Watanabe Y; Yamashita K
    Diabetes Res Clin Pract; 1991 Jul; 12(3):163-72. PubMed ID: 1832376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of acute administration of gliclazide on the glucose sensitivity of pancreatic B-cells in healthy subjects.
    Veneman TF; van Haeften TW; van der Veen EA
    Clin Sci (Lond); 1991 Jul; 81(1):101-6. PubMed ID: 1649715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy.
    Hosker JP; Rudenski AS; Burnett MA; Matthews DR; Turner RC
    Metabolism; 1989 Aug; 38(8):767-72. PubMed ID: 2668699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial continuous subcutaneous insulin infusion-induced normoglycemia.
    Della Casa L; del Rio G; Glaser B; Cerasi E
    Am J Med; 1991 Jun; 90(6A):37S-45S. PubMed ID: 1872303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gliclazide: metabolic and vascular effects--a perspective.
    Alberti KG; Johnson AB; Taylor R
    Metabolism; 1992 May; 41(5 Suppl 1):40-5. PubMed ID: 1574015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of gliclazide treatment on insulin secretion and beta-cell mass in non-insulin dependent diabetic Goto-Kakisaki rats.
    Dachicourt N; Bailbé D; Gangnerau MN; Serradas P; Ravel D; Portha B
    Eur J Pharmacol; 1998 Nov; 361(2-3):243-51. PubMed ID: 9865514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemobiological properties of gliclazide.
    Ziegler O; Drouin P
    J Diabetes Complications; 1994; 8(4):235-9. PubMed ID: 7833500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.